Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James Woods is active.

Publication


Featured researches published by James Woods.


Bioorganic & Medicinal Chemistry Letters | 2010

4-Aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators

Hui Xiong; Todd Andrew Brugel; Michael Balestra; Dean G. Brown; Kelly Brush; Caprice Hightower; Lindsay Hinkley; Valerie Hoesch; James Kang; Gerard M. Koether; John P. McCauley; Francis M. McLaren; Laura M. Panko; Thomas R. Simpson; Reed W. Smith; James Woods; Becky Brockel; Vijay Chhajlani; Reto Gadient; Nathan Spear; Linda A. Sygowski; Minli Zhang; Jalaj Arora; Nathalie Breysse; Julie Wilson; Methvin Isaac; Abdelmalik Slassi; Megan M. King

Positive allosteric modulation of metabotropic glutamate receptor 5 (mGluR5) is regarded as a potential novel treatment for schizophrenic patients. Herein we report the synthesis and SAR of 4-aryl piperazine and piperidine amides as potent mGluR5 positive allosteric modulators (PAMs). Several analogs have excellent activity and desired drug-like properties. Compound 2b was further characterized as a PAM using several in vitro experiments, and produced robust activity in several preclinical animal models.


Bioorganic & Medicinal Chemistry Letters | 2011

Synthesis and SAR of sulfoxide substituted carboxyquinolines as NK3 receptor antagonists

Hui Xiong; James Kang; James Woods; John P. McCauley; Gerard M. Koether; Jeffrey S. Albert; Lindsay Hinkley; Yan Li; Reto Gadient; Thomas R. Simpson

The neurokinin-3 (NK3) receptor is regarded as a potential novel target for treating patients with schizophrenia. Herein we report the synthesis and SAR of a series of C3-alkylsulfoxide substituted quinolines as potent NK3 receptor antagonists. These compounds have excellent NK3 functional activity, good selectivity and drug-like properties. Several key compounds have good in vitro/in vivo DMPK characteristics, and are active in a gerbil locomotor activity model.


Archive | 2002

Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3

Stefan Berg; Ratan Bhat; James Empfield; Sven Hellberg; Michael Klimas; James Woods


Archive | 2007

Nicotinic Acetylcholine Receptor Ligands 101

Hui-Fang Chang; Christopher R. Holmquist; Eifion Phillips; Timothy Martin Piser; Thomas R. Simpson; Rebecca Urbanek; James Woods; Hui Xiong


Archive | 2007

Amide substituted quinolines

Jeffrey S. Albert; Cristobal Alhambra; James Kang; Gerard M. Koether; Yan Li; Thomas R. Simpson; James Woods


Archive | 2006

ALKYLNITRILE QUINOLINES, AS NK-3 RECEPTOR LIGANDS

Jeffrey S. Albert; Cristobal Alhambra; James Kang; Gerard M. Koether; Thomas R. Simpson; James Woods; Yan Li


Archive | 2002

Compounds for the treatment of dementia related diseases

Stefan Berg; Ratan Bhat; James Empfield; Sven Hellberg; Michael Klimas; James Woods


Archive | 2008

Quinoline 3-Sulfonate Esters as Nk3 Receptor Modulators

Thomas R. Simpson; James Kang; Jeffrey S. Albert; Cristobal Alhambra; Gerard M. Koether; James Woods; Yan Li


Archive | 2006

Amide alkyl pyridiyl quinolines as nk3 receptor modulators

Jeffrey S. Albert; Cristobal Alhambra; James Kang; Gerard M. Koether; Thomas R. Simpson; James Woods; Yan Li


Archive | 2006

Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators

Thomas R. Simpson; Michael Balestra; Dean G. Brown; Cathy Dantzman; Glen Ernst; William Frietze; Christopher R. Holmquist; James Kang; Frances M. Mclaren; Reed W. Smith; James Woods

Collaboration


Dive into the James Woods's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yan Li

University of Minnesota

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge